A Chromogenic Factor X Assay with New Standardized Reagents

1979 ◽  
Author(s):  
P. Friberger ◽  
C. Lenne

A recently published method for Factor X (FX) assay (1) utilizing Russel’s Viper Venom (RW) and a chromogenic substrate has been further investigated by testing a large number of parameters, This method has been considered as a suitable method for monitoring coumarol treatment (Bergström et al).The conditions for the activation of FX by purified preparations of the RVV have been studied as well as the conditions for FXa determination with a new chromogenic substrate Bz-Ile-Glu(γ-piperidyl)-Gly-Arg-pNA (S-2337). Both purified factors and normal plasma have been used. The effect of plasma inhibitors as well as the selectivity of the method bas been studied.The reproducibility and stability of the different reagents and standards have been studied and found to be good.The amount of FXa activity obtained from normal human plasma has been titrated with FXa inhibitors of known purity.1) Aurell L. et al, Thromb. Res., 11, 595 (1977)2) Bergström et al, Thromb. Res., 12, 531 (1978)

1979 ◽  
Author(s):  
P Friberger ◽  
C Lenne

A recently published method for Factor X (FX) assay (1) utilizing Russel's Viper Venom (RVV) and a chromogenic substrate has been further investigated by testing a large number of parameters. This method has been considered as a suitable method for monitoring coumarol treatment (Bergström et al).The conditions for the activation of FX by purified preparations of the RVV have been studied as well as the conditions for FXa determination with a new chromogenic substrate Bz-Ile-Glu(γ-piperidyl)-Gly-Arg-pNA (S-2337). Both purified factors and normal plasma have been used. The effect of plasma inhibitors as well as the selectivity of the method has been studied.The reproducibility and stability of the different reagents and standards have been studied and found to be good.The amount of FXa activity obtained from normal human plasma has been titrated with FXa inhibitors of known purity.1) Aurell L. et al, Thromb. Res., 11, 595 (1977)2) Bergström et al, Thromb. Res., 12, 531 (1978)


1979 ◽  
Author(s):  
E. T. Yin ◽  
W. J. Salsgiver ◽  
O. Tangen

Circumstantial evidence suggested that normal human plasma contained a substance regulating the neutralization of F.Xa by F.Xa inhibitor(XaI), (Yin et.al.,Adv.Exper. Med. & Biol., 52 : 239, 1975, Plenum Press, N.Y.).This plasma component has now been isolated and partially purified in our laboratory, and tentatively designated as “Anti-XaI”.In experiments employing purified components, when Anti-XaI was incubated at 37°C with F.Xa, Xal and heparin for two minutes at pH7.5, the amount of F.Xa inhibited was inversely proportional to the Anti-XaI concentration. But, when the F.Xa was replaced by thrombin in the incubation mixture, the neutralization of thrombin clotting activity was undisturbed.Anti-XaI was found to be neither PF3 nor PF4.These and other data strongly suggest that the “Antithrombin III pathway” is more complex than currently believed to be. In circulating blood an equilibrium state must exist between Anti-XaI and XaI.Under certain conditions when the Anti-XaI activity is predominant the rate of F.Xa neutralization bv XaI then becomes slower than the activation of prothrombin to thrombin by F.Xa.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1554-1554 ◽  
Author(s):  
Azzah Al Masri ◽  
Tammy Price-Troska ◽  
Marta Chesi ◽  
Tae-Hoon Chung ◽  
Seungchan Kim ◽  
...  

Abstract Introduction: The analysis of what goes awry in a malignant cell has focused primarily on mutations of protein-encoding genes and their regulatory sequences. However, recent work on microRNA (miRNA) has shed light on the possible involvement of miRNA genes in human disease. miRNA are small “noncoding” or “non-messenger” RNAs of about 21–25 nucleotides in length that function as regulators of gene expression essentially by pairing to the mRNA of protein-coding genes to initiate mRNA degradation or repression of translation. We are interested in characterizing miRNA expression profiles in human myeloma cell lines (HMCLs) and myeloma patient samples. Multiple myeloma (MM) is a plasma cell tumor characterized by frequent chromosomal translocations. Materials and methods: The expression of miRNA in HMCLs, primary MM cells (hyperdiploid samples) and normal plasma cells was determined using human microRNA chips. The GenoExporerTM Human microRNA chips were developed by GenoSensor (Tempe, AZ) and the microarray contains 226 human microRNA sequences in addition to control sequences. The DNA oligo probes are synthesized and immobilized on the chips (1”x 3” standard glass microslide). The probes are designed based on the active mature miRNA sequences and some of their flanking sequences. Our analysis included seven myeloma patients (hyperdiploid MM), eight different HMCLs (MM1, 8226 with t(14;16); SKMM2, U266, INA-6 with t(11;14) and H929, KMS11, UTMC-2 with t(4;14)), and eight normal human plasma cells. The normal human plasma cells were collected at Mayo Clinic Rochester from bone samples of patients undergoing orthopedic surgery. For the assay 5–10 μg of total RNA per sample were used at a concentration of 1 μg/μL. The RNA is directly labeled with biotin and used as a target for the on-chip hybridization assays. A streptavidin-Alexa dye is used to stain the hybridized targets and the fluorescent signals are captured and analyzed. The gene signal intensities were normalized to tRNA signal intensity. Results: The primary MM cells and HMCLs displayed a distinctive miRNA expression profile compared with normal plasma cells. Using the GeneSpring 7 (Agilent Technologies, Palo Alto, CA) for gene expression analysis we have identified miRNA genes with significant variation in expression levels between tumor and normal samples including miR-125b, miR-133a, miR1, and miR-124a (p<0.01). Recently defined algorithms were used to identify putative targets for the miRNA genes of interest such as leukemia inhibitory factor (LIF) as targets of miR-125b and Stat3 and angiopoietin-1 precursor as targets of miR-124a (Lewis et al. 2003). Of note, miR-15 and miR-16, previously identified to be downregulated in CLL, were expressed at low levels in some MM patients and HMCLs, but not in the normal plasma cells. Further analysis will be carried out to validate the data from miRNA profiling using northern blot analysis or real-time RT-PCR to measure expression levels of miRNA genes and that of their target genes. Conclusion: Analysis of miRNA expression pattern (along with aCGH and gene expression profiling studies) will undoubtedly refine our understanding of the various genotypic subtypes of multiple myeloma.


Blood ◽  
1960 ◽  
Vol 16 (1) ◽  
pp. 943-957 ◽  
Author(s):  
IRVING SCHULMAN ◽  
MILA PIERCE ◽  
ABBY LUKENS ◽  
ZINET CURRIMBHOY

Abstract 1. A case of chronic thrombocytopenic purpura has been presented in which the pathogenesis appears to be due to congenital deficiency of a platelet-stimulating factor. 2. The factor exists in normal plasma and is stable on storage under normal blood banking conditions and on freezing. 3. The factor appears to act by stimulating megakaryocyte maturation and platelet production in an orderly and sequential manner.


1979 ◽  
Author(s):  
E.T. Yin ◽  
W.J. Salsgiver ◽  
O. Tangen

Circumstantial evidence suggested that normal human plasma contained a substance regulating the neutralization of F. Xa by F. Xa inhibitor (XaI), (Yin et.al., Adv. Exper. Med.& Biol., 52: 239, 1975, Plenum Press, N.Y.).This plasma component has now been isolated and partially purified in our laboratory, and tentatively designated as “Anti-Xal”.In experiments employing purified components, when Anti-Xal was incubated at 37°C with F. Xa. Xal and heparin for two minutes at pH7.5, the amount of F. Xa inhibited was inversely proportional to the Anti-XaI concentration. But, when the F. Xa was replaced by thrombin in the incubation mixture, the neutralization of thrombin clotting activity was undisturbed. Anti-Xa I was found to be neither PF3 nor PF6.These and other data strongly suggest that the “Antithrombin ill pathway” is more complex than currently believed to be. In circulating blood an equilibrium state must exist between Anti-Xal and Xal. Under certain conditions when the Anti-Xal activity is predominant the rate of F.Xa neutralization by Xal then becomes slower than the activation of prothrombin to thrombin by F.Xa.


1981 ◽  
Author(s):  
Richard A Marlar ◽  
John H Griffin

Human protein C (PC) is a vitamin K-dependent serine protease zymogen present in normal plasma. PC was activated with soluble thrombin, thrombin-Sepharose, trypsin-Sepharose or Russell’s viper venom. When activated protein C (APC) at 10 μg/ml was added to normal plasma for 3 min prior to assays, clotting was greatly inhibited. In prothrombin time, activated partial thromboplastin time, and partial thromboplastin time assays, the clotting times were prolonged from 24 to 68 sec, 57 to 616 sec, and 247 to > 1200 sec, respectively. Both calcium and phospholipid were needed for this potent anticoagulant activity. The thrombin time was unaffected. To test which coagulation factors in plasma were inactivated by APC, APC was added to normal human plasma for 3 min and residual clotting factor activities were assayed using appropriate deficient substrate plasmas. Only Factor V and Factor VIII activities were decreased by APC. PC and DFP-inhibited APC were not anticoagulant and did not decrease Factors V and VIII. APC hydrolyzed synthetic peptide substrates. The amidolytic activity of APC was inhibited by normal human plasma (50% of APC activity was lost in 10 min). APC inhibitory activity was not detectable in plasmas from 4 unrelated patients with combined Factor V/VIII deficiency whereas it was present in normal amounts in plasmas from patients with simple Factor V deficiency or Factor VIII deficiency. Thus, it appears that APC may regulate blood coagulation by enzymatically inactivating two critical cofactors, Factor Va and Villa. Moreover, APC itself may be regulated by a previously undescribed plasma protein inhibitor. It is suggested that the molecular basis for combined Factor V/VIII deficiency disease that exhibits simple autosomal recessive inheritance is a deficiency of APC inhibitor.


1981 ◽  
Author(s):  
Hyman Engelberg ◽  
Stephen Lee

The scientific literature is contradictory as to the normal presence of heparin activity in human blood. The question has physiologic and clinical significance. The purpose of this study was to investigate whether biologic heparin activity was demonstrable in extracts of normal human plasma. The method involved initial precipitation of the plasma proteins by methanol-acetone, proteolysis of the precipitated proteins by papase or trypsin, dialysis of the supernatant, lyophilization, and then assay. The final extract showed heparin activity using the Kabi chromogenic substrate, the activated partial thromboplastin time test, and the anti factor Xa procedure. The level of heparin activity was 10-25 units % (app. 1-2 mg/L of plasma). We conclude that endogenous heparin activity is present in normal human plasma at physiologically significant levels, and that it is protein bound.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4092-4092
Author(s):  
Hanspeter Rottensteiner ◽  
Katalin Varadi ◽  
Susanne Vejda ◽  
Jutta Schreiner ◽  
Herbert Gritsch ◽  
...  

Abstract A recombinant human CHO-expressed von Willebrand factor (rVWF) which consists of ultra-high molecular weight (UHMW) multimers resembles the VWF that is stored in Weibel-Palade bodies of endothelial cells. Once secreted into plasma, UHMW multimers are rapidly cleaved by ADAMTS13 and therefore are usually missing in VWF purified from plasma. We analyzed in vitro whether the cleavage of rVWF by ADAMTS13 is similar to the cleavage of plasma VWF by ADAMTS13, using a standard assay that depends on denaturing conditions (1.5 M urea) to expose the ADAMTS13 cleavage site of VWF. We explored the kinetics of ADAMTS13-mediated proteolysis of rVWF over time by exposing 1 VWF:Ag IU/ml of rVWF to various concentrations of recombinant and plasma-derived purified ADAMTS13, ranging from 4 mU/ml to 1 U/ml (corresponding to 0.4 to 100% of the normal human plasma concentration), and to ADAMTS13 present in normal human plasma and VWF-deficient plasma. The multimeric structure and function of VWF were analyzed by multiple assays to compare VWF before, during, and after proteolytic cleavage. In addition, the degradation kinetics of recombinant VWF were compared with those of a plasma-derived VWF product. Recombinant VWF was cleaved rapidly and with the same efficiency using recombinant or plasma-derived ADAMTS13. With 0.5 U/ml pADAMTS13 or rADAMTS13, VWF:RCo activity was below the detection limit of 0.17 IU/ml after 15 s. UHMW multimers disappeared within seconds at physiological concentrations of 0.5–1.0 U/ml ADAMTS13 (50–100% of the normal plasma concentration). Furthermore, UHMW were cleaved within 30 minutes with much lower concentrations of 10–30 mU/ml ADAMTS13 (1–3% of normal plasma concentration). The typical satellite bands appeared very early in an ADAMTS13 dose-dependent manner. Although plasma-derived VWF differs substantially from rVWF in its multimeric structure, the decrease in activity was similar for the recombinant and plasma-derived VWF. Specific cleavage of rVWF (3 IU VWF:Ag/ml) by rADAMTS13 (5 U/ml) was also demonstrated without urea under shear stress in the presence of platelets, detected by a monoclonal antibody (N10) that recognizes VWF only when cleaved by ADAMTS13. The combined data show that ADAMTS13 is able to readily cleave human rVWF even at low concentrations and that the UHMW multimeric fraction of human rVWF is removed within minutes by ADAMTS13 in vitro.


1987 ◽  
Vol 65 (11) ◽  
pp. 2319-2328 ◽  
Author(s):  
A. David Purdon ◽  
Arline Y. Loh ◽  
Daniel H. Osmond

Standard methods for determining prorenin-renin concentrations in plasma (PRC) and other tissues require the addition of exogenous renin substrate (angiotensinogen) to improve the kinetics of the renin reaction. We studied the effects of substrate prepared from normal human plasma fraction Cohn IV-4, or from nephrectomized (2NX) sheep plasma, on PRC of normal and 2NX human plasmas before and after prorenin activation by acid, cold, and trypsin, and compared the results with plasma renin activities (PRA, no added substrate). Plasmas from 2NX men exhibited negligible basal PRA, indicating that very little, if any, renin had been formed from the extrarenal prorenin they contained, and suggesting the lack of an endogenous prorenin activating mechanism, or "convertase," of probable renal origin. Prorenin was demonstrable by tryptic activation, more than by acid or cold, at up to about 30% of normal. Addition of Cohn IV-4 substrate to 2NX plasma unexpectedly produced (i) a basal PRC value higher than in normal plasma, (ii) total renin values after activation by acid, cold, and trypsin that were much closer to normal values than reflected by PRA methodology, without a commensurate increase (if anything a decrease) in prorenin as a percentage of total renin estimated by all activation methods, and (iii) substantial equalization of activation effects such that trypsin was no longer more effective than acid and cold (and this was also noted with normal plasma). The skewing effect of adding Cohn IV-4 substrate on the PRC of 2NX plasma was much greater than in normal plasma, even though 2NX plasma already had an above normal level of endogenous substrate and should have been influenced less. Enhancement of PRC was very pronounced even when Cohn IV-4 was added to make up only 9% of total (endogenous + exogenous) substrate in the incubation system, suggesting that it was not the added substrate but a renin-generating contaminant that inflated the PRC. Such inflation could be blocked by adding protease inhibitors, suggesting that the responsible protease(s) acted as a prorenin "convertase" that generated new renin from renal and (or) extrarenal prorenin contributed by the added substrate, as well as by the plasma being assayed. One component of convertase could be kallikrein, which was identified by chromogenic assay, the importance of which relative to total convertase activity is unknown. The convertase content of substrate from 2NX sheep plasma seemed to be low (again suggesting loss due to 2NX, i.e., its renal origin), but it contributed extrarenal prorenin from which additional renin was apparently formed by the action of convertase provided by normal human plasma in the PRC assay. Thus, both human Cohn IV-4 and 2NX sheep substrates can apparently contribute renal and (or) extrarenal prorenin and various amounts of convertase which can, along with the actual substrate, greatly influence the PRC assay, and do so to a higher degree in some plasmas than in others. We also found that activation by cold and trypsin did not destroy endogenous plasma substrate (if anything increased it), suggesting activation of a "prosubstrate," while acid activation destroyed only about half of the measurable substrate. The presence of convertase in the Cohn IV-4 fraction suggests it must have come from the original whole plasma. This, along with existing prorenin, has the potential to be a functional renin-producing pathway in normal blood which is lost after nephrectomy owing to the disappearance of a renal "convertase."


Sign in / Sign up

Export Citation Format

Share Document